Posted by Michael Wonder on 11 Jul 2020
How can cancer drug prices better match their benefits? Germany offers a cost-saving model
10 July 2020 - After Germany revamped its approach to purchasing medicines a decade ago, the prices negotiated by the government for cancer treatments were more closely aligned with clinical benefits, a new study finds.
Moreover, the effort led to a 25% drop in prices one year after product launches, prompting the researchers to suggest U.S. policy makers should consider Germany as a cost-saving model.
In reaching their conclusion, the researchers examined data for 57 cancer treatments that were launched in Germany from 2002 to 2017.
